Study Description
The purpose of the study is to find out if iptacopan is effective and safe in adult patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) who switch from their current standard of care treatment (eculizumab or ravulizumab) to study treatment, iptacopan/LNP023.
This is a multicenter, single-arm, open label trial, with iptacopan treatment for 24 weeks in adult PNH patients.
This study is comprised of two periods:
A Screening period lasting up to 8 weeks.
A 24-week open-label, iptacopan Treatment period.
After completion of the treatment period, participants who continue to benefit from the iptacopan treatment based on the study doctor's evaluation will be able to join the Roll-over extension study.
Interventions
Iptacopan
Eligibility Criteria
Inclusion Criteria:
Signed informed consent must be obtained prior to participation in the study.
Male and female participants ≥ 18 years of age, at the time of ICF signatures and with a diagnosis of PNH confirmed by treating physician.
Stable regimen (dose and intervals) of anti-C5 antibody treatment (either eculizumab or ravulizumab) for at least 6 months prior to screening
Mean hemoglobin level ≥10 g/dL
Vaccination against Neisseria meningitidis and S. pneumoniae infection are required prior to the start of iptacopan treatment.
If not received previously, vaccination against Haemophilus influenzae infections is recommended, if available and according to local regulations.
Ability to communicate well with the investigator, to understand and comply with the requirements of the study
Other protocol -defined inclusion criteria may apply at the end.
Exclusion Criteria:
Participation in any other investigational drug trial or use of other investigational drugs at the time of enrollment
Patients requiring red blood cell transfusion in the 6 months prior to screening or during screening
History of stem cell transplantation or any solid organ transplantation
Active systemic bacterial, viral (incl. COVID-19) or fungal infection within 14 days prior to study drug administration
Presence of fever ≥ 38.0 °C (100.4 °F) within 7 days prior to study drug administration
Human immunodeficiency virus (HIV) infection (known history of HIV or test positive for HIV antibody at Screening)
A history of recurrent invasive infections caused by encapsulated organisms, e.g. meningococcus or pneumococcus
Unstable medical condition including, but not limited to, myocardial ischemia, active gastrointestinal bleeding, coexisting chronic anemia unrelated to PNH, or unstable thrombotic event not amenable to active treatment as judged by the investigator at Screening.
History of cancer of any part of the body within the past 5 years,
Ongoing drug or alcohol abuse that could interfere with patient's participation in the trial.
Any medical condition deemed likely to interfere with the patient's participation in the study
Female patients who are pregnant or breastfeeding, or intending to conceive during the course of the study
Study Location
Novartis Investigative Site
Recruiting
Nice,06202,France
Novartis Investigative Site
Recruiting
Paris 10,75475,France
Novartis Investigative Site
Recruiting
Nantes Cedex 1,44093,France
Novartis Investigative Site
Recruiting
Ulm,89081,Germany
Novartis Investigative Site
Recruiting
Dresden,01307,Germany
Novartis Investigative Site
Recruiting
Aachen,52074,Germany
Novartis Investigative Site
Recruiting
Bassano Del Grappa,VI,36061,Italy
Novartis Investigative Site
Recruiting
San Giovanni Rotondo,FG,71013,Italy
Novartis Investigative Site
Recruiting
Firenze,FI,50134,Italy
Novartis Investigative Site
Recruiting
Avellino,AV,83100,Italy
Novartis Investigative Site
Recruiting
Seoul,06351,Korea, Republic of
Novartis Investigative Site
Recruiting
Barcelona,Catalunya,08036,Spain
Novartis Investigative Site
Recruiting
Aydin,09100,Turkey
Novartis Investigative Site
Recruiting
Istanbul,34093,Turkey
Novartis Investigative Site
Recruiting
Leeds,LS9 7TF,United Kingdom
Novartis Investigative Site
Recruiting
London,SE5 9RS,United Kingdom
Novartis Investigative Site
Recruiting
Cleveland,Ohio,44195,United States
Novartis Investigative Site
Recruiting
Worcester,Massachusetts,01665,United States
Novartis Investigative Site
Recruiting
Duarte,California,91010,United States
Novartis Investigative Site
Recruiting
Saint Louis,Missouri,63110,United States
Novartis Investigative Site
Recruiting
Los Angeles,California,90033,United States
Novartis Investigative Site
Recruiting
Durham,North Carolina,27710,United States
Novartis Investigative Site
Recruiting
Boston,Massachusetts,02114,United States
Novartis Investigative Site
Recruiting
Miami Lakes,Florida,33014,United States
Novartis Investigative Site
Recruiting
Bronx,New York,10461,United States
Novartis Investigative Site
Recruiting
Minneapolis,Minnesota,55455,United States
Novartis Investigative Site
Recruiting
Augusta,Georgia,30912,United States
Novartis Investigative Site
Recruiting
Greenville,South Carolina,29615,United States
Novartis Investigative Site
Recruiting
Torrance,California,90509-2910,United States
Novartis Investigative Site
Recruiting
Cerritos,California,90703,United States
Worldwide Contacts
If the location of your choosing does not feature any contact detail, please reach out using the information below.